Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware,[2] and Morges, Switzerland.[3]
The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991[4] and Incyte Genomics, Inc. of Delaware.[5] The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.[6]
Incyte Corporation currently develops and manufacturers prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.
History
In 2014, Incyte named Hervé Hoppenot president and CEO, and in 2015 he was appointed chairman of the Board of Directors.[7][8] Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003.[8]
In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1monoclonal antibody, SHR-1210, in a deal worth $795+ million.[9]
In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys.[10] On March 3, 2020, the agreement received antitrust clearance and thus became effective.[11]
As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[15][16] It gained EU approval in February 2017.[17] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[18][19] In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant.[20][21]
^"Incyte to establish European headquarters in Geneva". 15 July 2020. Retrieved 12 September 2021. New facility to serve as European base for Incyte's drug development operations, and provides efficient access to key clinical trial experts and institutions.
